Propranolol plus chemotherapy and immunotherapy before stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding a blood pressure medicine (propranolol) to standard chemotherapy and immunotherapy before surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of stomach or gastroesophageal junction cancer that has not spread to distant organs and can be removed with surgery.
- You must be between 18 and 75 years old.
- Your heart and lungs must work well, with a resting heart rate of at least 60 beats per minute and blood pressure not too low.
- You must be in good overall health (able to do daily activities without help).
- You cannot have had any previous chemotherapy, immunotherapy, or radiation for this cancer.
- You must not be pregnant or breastfeeding and agree to use birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
This trial tests combining chemotherapy (FOLFOX) with an immunotherapy drug (Toripalimab) before and after surgery for a type of stomach cancer called HER2-negative adenocarcinoma of the esophagogastric junction. It may help shrink the tumor and improve outcomes.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.